Organogenesis Holdings, Inc. Class A (ORGO)

In September and October 2025, ORGO's stock experienced significant weakness due to financial underperformance and market skepticism. In February 2026, the company reported strong full-year 2025 earnings, exceeding expectations. Fiscal 2026 guidance anticipates a near-term revenue decline, leading to investor sentiment deteriorating. In April 2026, positive news regarding PuraPly®AM and ReNu® caused shares to jump.

Demand seasonality exists for Organogenesis Holdings, Inc.'s products and services, with demand for advanced wound care and surgical/sports medicine products varying throughout the year.

Organogenesis Holdings, Inc. is a regenerative medicine company focused on developing, manufacturing, and commercializing advanced product solutions for wound care, surgical, and sports medicine markets. The company operates in the Healthcare sector, specifically in Biotechnology and Drug Manufacturers - Specialty & Generic industries, with products categorized into Advanced Wound Care and Surgical & Sports Medicine.

Organogenesis Holdings, Inc. is headquartered in Canton, Massachusetts, and has additional offices and manufacturing facilities in San Diego, California, as well as offices in Birmingham, Alabama, and St. Petersburg, Florida. All products are manufactured in the United States, and the company has an international office in Reinach, Switzerland.

Organogenesis's brand reputation experienced fluctuations in the past year. Late 2025 saw negative sentiment due to financial underperformance. Recent positive developments in April 2026, such as the successful clinical trial for PuraPly®AM and the positive FDA meeting regarding ReNu®, are likely to have a favorable impact on the company's brand reputation.

Organogenesis Holdings, Inc. has a mix of institutional and individual investors, with institutional investors holding a significant portion of the shares. Major institutional owners include Morgan Stanley, Soleus Capital Management, L.P., and Vanguard Group Inc. Key individual owners include Alan A. Ades, Dennis Erani, and Glenn H. Nussdorf, with Alan A. Ades being the largest individual shareholder.